https://biotechmorning.com/news/odyssey-therapeutics-304m-ipo-tpg-placement Biotech Morning en 2026-06-03T14:21:59.643Z Odyssey Just Raised $304M Before Most Biotechs Finish Their Slide Decks https://biotechmorning.com/news/travere-billion-dollar-btk-inhibitor-deal Biotech Morning en 2026-06-03T14:21:08.956Z Travere's $1.1B Bet on a Drug It Didn't Build https://biotechmorning.com/news/bms-bispecific-adc-asco-trop2-threat Biotech Morning en 2026-06-03T14:20:15.237Z BMS Just Showed Up to the ADC Party With a Weapon Nobody Expected https://biotechmorning.com/news/lilly-ascidian-rna-exon-editing-kidney-disease-deal Biotech Morning en 2026-06-03T14:19:24.034Z Lilly Just Bet $1.9B on an Editing Trick That Doesn't Touch DNA https://biotechmorning.com/news/celcuity-10-billion-vision-one-drug Biotech Morning en 2026-06-03T14:18:25.360Z Celcuity Wants to Be a $10 Billion Company. It Has One Drug. https://biotechmorning.com/news/cytokinetics-acacia-hcm-non-obstructive-readout Biotech Morning en 2026-06-03T14:17:31.985Z Cytokinetics Waited 27 Years for Its First Drug. Now It Wants to Double Down. https://biotechmorning.com/news/newlimit-435m-cellular-rejuvenation-funding Biotech Morning en 2026-06-03T14:16:41.375Z The Coinbase Guy Wants to Make Your Liver 20 Years Younger https://biotechmorning.com/news/roche-giredestrant-first-line-breast-cancer-miss Biotech Morning en 2026-06-03T14:15:51.270Z Roche's Big Bet on Replacing a Cancer Drug Staple Just Hit a Wall https://biotechmorning.com/news/intellia-crispr-phase-3-hae-results Biotech Morning en 2026-06-03T14:14:55.447Z One Shot to Silence a Gene Forever https://biotechmorning.com/news/legend-biotech-in-vivo-car-t-data Biotech Morning en 2026-06-03T14:14:00.460Z Legend Biotech Just Skipped the Factory. The Results Are Wild. https://biotechmorning.com/news/telix-pluvicto-challenger-prostate-cancer Biotech Morning en 2026-06-02T14:23:11.191Z Novartis Built a $2 Billion Monopoly in Radioligand Therapy. Telix Just Showed Up. https://biotechmorning.com/news/servier-edgewise-muscular-dystrophy-pill-deal Biotech Morning en 2026-06-02T14:22:20.147Z A $2.7 Billion Bet That a Simple Pill Can Fight Muscular Dystrophy https://biotechmorning.com/news/gsk-velzatinib-challenge-gleevec-gist Biotech Morning en 2026-06-02T14:21:31.442Z The Drug That Could Dethrone a 24-Year-Old Cancer King https://biotechmorning.com/news/abivax-efficacy-cancer-safety-stock-drop Biotech Morning en 2026-06-02T14:20:34.242Z The Best Ulcerative Colitis Drug Nobody Wants to Buy Stock In https://biotechmorning.com/news/fda-kills-fulcrum-sickle-cell-drug Biotech Morning en 2026-06-02T14:19:39.105Z The FDA Just Killed a Sickle Cell Drug — in Biotech's Hottest Market https://biotechmorning.com/news/ucb-candid-therapeutics-2-billion-acquisition-2 Biotech Morning en 2026-06-02T14:18:46.841Z UCB Just Ditched a Biotech's IPO Plans With a $2 Billion Phone Call